Abbott (ABT) Reports In-Line Q4 EPS; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbott Labs (ABT) PT Raised to $140 at BTIG
January 22, 2025 1:54 PM ESTBTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $139.00) while maintaining a Buy rating.
The analyst comments "Abbott reported a Q4 total revenue miss, much of which we attribute to greater Fx headwinds and lower-than-expected COVID testing revenue, and adj. EPS in line with expectations (see our flash note here). In our view, the main message on the call was the positive 2025 outlook, which called for above-consensus organic sales growth, a return to DD adj. EPS growth, and an impressive 150 bps of... More
